| Evaluable for safety, n | 46 |
| Evaluable for efficacy, n | 45∗ |
| Median age, y (range) | 64 (43-83) |
| Male/female, n | 33/13 |
| ECOG, 0/1/2, n | 6/38/2 |
| Prior therapy regimens, median (range) | 2 (1-6) |
| Refractory to immediate prior therapy, n (%) | 18 (39%) |
| Prior anti-CD20, n (%) | 39 (85%) |
| Prior chemoimmunotherapy, n (%) | 35 (76%) |
| Prior targeted therapy, n (%) | 30 (65%) |
| Prior BTKi (ibrutinib/acalabrutinib), n (%) | 26 (57%) |
| Refractory to prior BTK inhibitor, % (n/N) | 69% (18/26) |
| BTK or PLCγ mutation detected, % (n/N) | 71% (10/14) |
| Prior PI3K inhibitor, n (%) | 3 (7%) |
| Prior venetoclax, n (%) | 1 (2%) |
| High risk features | |
| 11q deletion | 10/46 (22%) |
| 17p deletion | 10/46 (22%) |
| TP53 mutation | 10/33 (30%) |
| NOTCH1 mutation | 8/26 (31%) |
| SF3B1 mutation | 5/26 (19%) |
| IGHV unmutated | 28/38 (74%) |
| Evaluable for safety, n | 46 |
| Evaluable for efficacy, n | 45∗ |
| Median age, y (range) | 64 (43-83) |
| Male/female, n | 33/13 |
| ECOG, 0/1/2, n | 6/38/2 |
| Prior therapy regimens, median (range) | 2 (1-6) |
| Refractory to immediate prior therapy, n (%) | 18 (39%) |
| Prior anti-CD20, n (%) | 39 (85%) |
| Prior chemoimmunotherapy, n (%) | 35 (76%) |
| Prior targeted therapy, n (%) | 30 (65%) |
| Prior BTKi (ibrutinib/acalabrutinib), n (%) | 26 (57%) |
| Refractory to prior BTK inhibitor, % (n/N) | 69% (18/26) |
| BTK or PLCγ mutation detected, % (n/N) | 71% (10/14) |
| Prior PI3K inhibitor, n (%) | 3 (7%) |
| Prior venetoclax, n (%) | 1 (2%) |
| High risk features | |
| 11q deletion | 10/46 (22%) |
| 17p deletion | 10/46 (22%) |
| TP53 mutation | 10/33 (30%) |
| NOTCH1 mutation | 8/26 (31%) |
| SF3B1 mutation | 5/26 (19%) |
| IGHV unmutated | 28/38 (74%) |
ECOG, Eastern Cooperative Oncology Group performance status; IGHV, immunoglobulin heavy-chain variable region gene.
One patient was removed from study before response assessment due to noncompliance.